PE20090302A1 - Anticuerpo multiespecifico - Google Patents

Anticuerpo multiespecifico

Info

Publication number
PE20090302A1
PE20090302A1 PE2008000664A PE2008000664A PE20090302A1 PE 20090302 A1 PE20090302 A1 PE 20090302A1 PE 2008000664 A PE2008000664 A PE 2008000664A PE 2008000664 A PE2008000664 A PE 2008000664A PE 20090302 A1 PE20090302 A1 PE 20090302A1
Authority
PE
Peru
Prior art keywords
gro
antibody
seq
referred
specific antibody
Prior art date
Application number
PE2008000664A
Other languages
English (en)
Inventor
Stephanie Jane Clegg
Eric Dobrzynski
Jonathan H Ellis
Volker Germaschewski
Alexis Paul Godillot
Zdenka Luzmila Jonak
Alan P Lewis
John R White
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20090302A1 publication Critical patent/PE20090302A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

REFERIDA A UN ANTICUERPO QUE TIENE ESPECIFICIDAD MULTIPLE POR LAS PROTEINAS IL-8 HUMANA, Gro-ALFA, Gro-BETA, Gro-GAMMA Y ENA-78, DONDE DICHO ANTICUERPO COMPRENDE REGIONES VARIABLES DE CADENA PESADA Y LIGERA CODIFICADAS POR SECUENCIAS DE NUCLEOTIDOS QUE COMPRENDEN LAS SECUENCIAS DE LA SEC ID N‘:1 Y LA SEC ID N‘:3 O MODIFICACIONES DE SECUENCIAS CONSERVATIVAS DE LAS MISMAS. TAMBIEN ESTA REFERIDA A UN HIBRIDOMA O TRANSFECTOMA, UN VECTOR DE EXPRESION Y A UN PROCEDIMIENTO DE PREPARACION. DICHO ANTICUERPO ES UTIL EN EL TRATAMIENTO DE OSTEOARTRITIS, ARTRITIS REUMATOIDE, ARTRITIS EROSIVA, ENTRE OTRAS
PE2008000664A 2007-04-17 2008-04-16 Anticuerpo multiespecifico PE20090302A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91222907P 2007-04-17 2007-04-17
US4413208P 2008-04-11 2008-04-11

Publications (1)

Publication Number Publication Date
PE20090302A1 true PE20090302A1 (es) 2009-04-03

Family

ID=39872910

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000664A PE20090302A1 (es) 2007-04-17 2008-04-16 Anticuerpo multiespecifico

Country Status (30)

Country Link
US (3) US20080262203A1 (es)
EP (1) EP2146745B1 (es)
JP (1) JP5441885B2 (es)
KR (1) KR101560841B1 (es)
CN (1) CN101687035B (es)
AU (1) AU2008243049B2 (es)
BR (1) BRPI0810250A8 (es)
CA (1) CA2684626C (es)
CL (1) CL2008001071A1 (es)
CO (1) CO6251323A2 (es)
CR (1) CR11116A (es)
CY (1) CY1116671T1 (es)
DK (1) DK2146745T3 (es)
DO (1) DOP2009000236A (es)
EA (1) EA024621B1 (es)
ES (1) ES2547475T3 (es)
HK (1) HK1136970A1 (es)
HR (1) HRP20150937T1 (es)
HU (1) HUE027584T2 (es)
IL (1) IL201440A (es)
MA (1) MA31310B1 (es)
MX (1) MX2009011153A (es)
MY (1) MY150525A (es)
NZ (1) NZ580239A (es)
PE (1) PE20090302A1 (es)
PL (1) PL2146745T3 (es)
PT (1) PT2146745E (es)
SI (1) SI2146745T1 (es)
TW (1) TWI473815B (es)
WO (1) WO2008130969A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
TWI564021B (zh) 2008-04-11 2017-01-01 Chugai Pharmaceutical Co Ltd Repeated binding of antigen to antigen binding molecules
CA2783563A1 (en) * 2009-12-07 2011-06-16 Decimmune Therapeutics, Inc. Anti-inflammatory antibodies and uses therefor
US20120315267A1 (en) * 2010-02-09 2012-12-13 Glaxosmithkline Llc Novel uses
TWI761912B (zh) 2010-11-30 2022-04-21 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
WO2013166099A1 (en) * 2012-05-01 2013-11-07 Glaxosmithkline Llc Novel antibodies
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
CN113831406A (zh) 2012-08-24 2021-12-24 中外制药株式会社 FcγRIIb特异性Fc区变体
EP2970445A4 (en) 2013-03-12 2017-02-22 Decimmune Therapeutics Inc. Humanized anti-n2 antibodies
US9290570B2 (en) 2013-03-15 2016-03-22 Eli Lilly And Company Pan-ELR+ CXC Chemokine Antibodies
JO3580B1 (ar) 2013-03-15 2020-07-05 Lilly Co Eli أجسام مضادة لكيموكين elr+ cxc شامل
CA2908350C (en) 2013-04-02 2023-08-08 Futa Mimoto Fc region variant
EP2796875B8 (en) * 2013-04-23 2020-11-25 Albert-Ludwigs-Universität Freiburg Inhibitors of proteins specific for the secretome of a chondrocyte for use in the treatment of breast cancer metastasis
KR20160021125A (ko) * 2013-05-17 2016-02-24 쌩뜨레 나티오날 데 라 르세르쉬 생띠끄 (씨. 엔. 알. 에스) 항-cxcl1, cxcl7 및 cxcl8 항체 및 이들의 용도
PE20171111A1 (es) 2014-12-19 2017-08-07 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
WO2018025982A1 (ja) 2016-08-05 2018-02-08 中外製薬株式会社 Ｉｌ－８関連疾患の治療用又は予防用組成物
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2019036605A2 (en) * 2017-08-17 2019-02-21 Massachusetts Institute Of Technology MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
EP3694545A4 (en) 2017-10-11 2021-12-01 Board Of Regents, The University Of Texas System HUMAN PD-L1 ANTIBODIES AND METHOD OF USING THEM
CN116327926A (zh) 2018-03-15 2023-06-27 中外制药株式会社 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
AU2019239568A1 (en) * 2018-03-23 2020-09-17 Board Of Regents, The University Of Texas System Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor
WO2021113697A1 (en) * 2019-12-05 2021-06-10 Seagen Inc. Anti-avb6 antibodies and antibody-drug conjugates
US20220080044A1 (en) * 2020-09-14 2022-03-17 National Yang-Ming University Method for preventing or treating peripheral arterial occlusive disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE913192A1 (en) * 1990-09-12 1992-02-25 Scripps Research Inst Active site of interleukin-8: polypeptide analogs and¹antibodies
US6448379B1 (en) * 1993-09-14 2002-09-10 Chiron Corporation IL8 inhibitors
JP4423680B2 (ja) * 1995-06-07 2010-03-03 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Ｃｄｒ−グラフト化抗組織因子抗体及びその使用
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
AR030753A1 (es) * 2000-09-25 2003-09-03 Smithkline Beecham Corp Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas
CZ20031307A3 (cs) * 2000-10-13 2003-10-15 Biogen, Inc. Humanizované protilátky k lymfotoxinovému beta receptoru
AU2002257567A1 (en) 2001-04-26 2002-11-11 Dakocytomation Denmark A/S Pan-specific monoclonal antibody
US20040022726A1 (en) * 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
JP4739763B2 (ja) * 2002-12-16 2011-08-03 ゲンマブ エー／エス インターロイキン８（ｉｌ−８）に対するヒトモノクローナル抗体
AU2003303543A1 (en) * 2002-12-26 2004-07-29 Chugai Seiyaku Kabushiki Kaisha Agonist antibody against heteroreceptor
WO2005094882A1 (en) * 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
US20110129412A1 (en) * 2005-06-02 2011-06-02 Astrazeneca Ab Antibodies Directed to CD20 and Uses Thereof
CA2678008C (en) * 2005-06-17 2013-07-30 Imclone Systems Incorporated Methods of treating a secondary bone tumor with anti-pdgfralpha antibodies
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
WO2007056411A2 (en) * 2005-11-08 2007-05-18 Genentech, Inc. Method of producing pan-specific antibodies
US8454960B2 (en) * 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains

Also Published As

Publication number Publication date
TWI473815B (zh) 2015-02-21
IL201440A (en) 2016-08-31
WO2008130969A3 (en) 2008-12-18
TW200906855A (en) 2009-02-16
EP2146745A4 (en) 2011-11-30
IL201440A0 (en) 2010-06-16
WO2008130969A2 (en) 2008-10-30
CA2684626A1 (en) 2008-10-30
HK1136970A1 (en) 2010-07-16
EP2146745A2 (en) 2010-01-27
EA200970954A1 (ru) 2010-08-30
CR11116A (es) 2010-03-22
CA2684626C (en) 2014-11-04
CN101687035B (zh) 2013-06-12
MY150525A (en) 2014-01-30
JP2010524469A (ja) 2010-07-22
PT2146745E (pt) 2015-10-14
ES2547475T3 (es) 2015-10-06
BRPI0810250A2 (pt) 2014-10-14
US8828384B2 (en) 2014-09-09
BRPI0810250A8 (pt) 2017-02-21
AU2008243049A1 (en) 2008-10-30
CY1116671T1 (el) 2017-03-15
SI2146745T1 (sl) 2015-10-30
HRP20150937T1 (hr) 2015-10-09
US20140010807A1 (en) 2014-01-09
DK2146745T3 (en) 2015-09-14
HUE027584T2 (en) 2016-11-28
CL2008001071A1 (es) 2009-05-22
EP2146745B1 (en) 2015-06-17
CO6251323A2 (es) 2011-02-21
MA31310B1 (fr) 2010-04-01
KR20100020946A (ko) 2010-02-23
EA024621B1 (ru) 2016-10-31
MX2009011153A (es) 2009-10-30
JP5441885B2 (ja) 2014-03-12
PL2146745T3 (pl) 2015-11-30
US20080262203A1 (en) 2008-10-23
US8496932B2 (en) 2013-07-30
NZ580239A (en) 2012-07-27
CN101687035A (zh) 2010-03-31
KR101560841B1 (ko) 2015-11-11
AU2008243049B2 (en) 2011-04-21
US20110229475A1 (en) 2011-09-22
DOP2009000236A (es) 2009-11-15

Similar Documents

Publication Publication Date Title
PE20090302A1 (es) Anticuerpo multiespecifico
CL2008002349A1 (es) Molecula de anticuerpo que se une a cd37 humano; molecula de adn que la codifica; vector de expresion y celula huesped; metodo para producir dicho anticuerpo; composicion farmaceutica que la comprende; método in vitro para suprimir células b que expresan cd37 en una población de células.
PE20061395A1 (es) Anticuerpos contra miostatina
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
PE20120205A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y citarabina
PE20141045A1 (es) Proteinas de union a bcma (cd269/tnfrsf17)
PE20121034A1 (es) Anticuerpos anti-factor d humanizados
PE20131412A1 (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
PE20140004A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y bortezomib
PE20141162A1 (es) Anticuerpos anti-il-23
PE20081478A1 (es) Anticuerpos cd44
PE20080035A1 (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
PE20131413A1 (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
PE20080739A1 (es) Anticuerpos para il-17a
AR074221A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y ciclofosfamida
AR065433A1 (es) Anticuerpos anti-cxcl13
PE20140633A1 (es) Anticuerpos neutralizadores anti-ccl20
PE20080111A1 (es) Anticuerpos contra la il-22 humana y usos para los mismos
ES2675375T3 (es) Anticuerpos monoclonales contra claudina 18 para el tratamiento del cáncer
PE20141546A1 (es) Anticuerpos anti-cd134(ox40) y sus usos de los mismos
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
UY30524A1 (es) Anticuerpos dirigidos a avb(beta)6 y sus usos
GT201200058A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
AR060417A1 (es) Anticuerpos dirigidos contra receptor del activador de plasminogeno tipo uroquinasa (upar) y usos de dichos anticuerpos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed